Navigation Links
ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on May 17
Date:5/10/2010

SAN DIEGO, May 10 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Rodman & Renshaw Annual Global Investment Conference on Monday, May 17, 2010, at 11:05 a.m. local time (6:05 a.m. Eastern time), in the Albemarle Suite at the Grosvenor House Hotel in London.

Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals Web site at www.adventrx.com.  An archived presentation will be available on the Web site for 30 days.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use.  More information can be found on the Company's Web site at www.adventrx.com.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
10. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)... 8, 2017 ... Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, September 18 th .The ... free MRI brain scans to the public.Where:  BTF,s ... at 501 K Street NW, Washington, D.C.What:BTF brings its nationwide initiative, the ...
(Date:9/7/2017)... INDIANAPOLIS , Sept. 7, 2017  Eli ... today announced actions to streamline operations to more ... to improve its cost structure. Global workforce reductions, ... program, are expected to impact approximately 3,500 positions. ... the company expects annualized savings of approximately $500 ...
(Date:9/7/2017)... STOCKHOLM , Sept. 7, 2017 NuvoAir ... Air Smart Spirometer, announced today a partnership with Novartis Pharma ... partnership solidifies NuvoAir,s position as the leading mobile spirometry platform ... respiratory patients. ... spirometry test ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... September 19, 2017 , ... Driving Dynamics Inc., announced ... Company by Training Industry Inc. as part of its mission to continually monitor the ... to the first annual 2017 Top 20 Health and Safety Training Companies list was ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... the success of the annual PAINWeek National Conference. On October 7, at the ... an educational and exciting program providing busy clinicians and allied healthcare practitioners with ...
(Date:9/19/2017)... ... September 19, 2017 , ... Spain’s popular ... ACPG Laboratories, is coming soon to RonnieColemanNutrition.com. , ACPG Laboratories has been ... a trusted, well-respected brand reliant on the healing properties of plants, a proven ...
(Date:9/19/2017)... ... September 19, 2017 , ... Bone Solutions Inc. (BSI), ... magnesium-based orthopedic medical device, OsteoCrete®. OsteoCrete® bone void filler is designed to assist ... incorporate magnesium, a critical property for bone health and development. , “We’re excited ...
(Date:9/19/2017)... ... September 19, 2017 , ... For decades doctors, nurses, and ... attack by measuring their risk factors and calculating their cardiovascular disease (CVD) risk in ... the same way CVD is predicted today: an estimated 10-year risk prediction! , Imagine ...
Breaking Medicine News(10 mins):